Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 12/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.41 |
| ▸ | XIAP | P98170 | 3/20 | 0.41 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331054 | 0.91 | MME (0.52) | MMEACELCKCASP1XIAP | |
| SCHEMBL1330899 | 0.85 | MME (0.51) | MMEACELCKCASP1XIAP | |
| SCHEMBL1329301 | 0.83 | MME (0.49) | MMEACELCKCASP1XIAP | |
| SCHEMBL1329608 | 0.82 | MME (0.57) | MMEACELCKCASP1 | |
| SCHEMBL1331111 | 0.80 | XIAP (0.52) | ACEXIAPBIRC3BIRC2 | |
| SCHEMBL1329628 | 0.79 | XIAP (0.58) | ACEXIAPBIRC3BIRC2 | |
| SCHEMBL12128043 | 0.79 | XIAP (0.58) | ACEXIAPBIRC3BIRC2 | |
| SCHEMBL4770315 | 0.78 | ACE (0.61) | MMEACELCKCASP1 | |
| SCHEMBL1328679 | 0.77 | MME (0.47) | MMEACELCKXIAPBIRC3 | |
| SCHEMBL1330834 | 0.77 | MME (0.56) | MMEACELCKCASP1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | MME 3989/4885ACE 3425/4885LCK 600/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | MME 3990/4885ACE 3421/4885LCK 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.